Journal of Bone Oncology

Papers
(The H4-Index of Journal of Bone Oncology is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
#15. Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma94
From bimodal to unimodal: The transformed incidence of osteosarcoma in the United States50
Postoperative outcomes of subaxial cervical spine metastasis: Comparison among the anterior, posterior, and combined approaches45
Serum total periostin is an independent marker of overall survival in bone metastases of lung adenocarcinoma43
Chinese expert consensus on the diagnosis and clinical management of medication-related osteonecrosis of the jaw39
MAT2A inhibits the ferroptosis in osteosarcoma progression regulated by miR-26b-5p36
Senescence in the bone marrow microenvironment: A driver in development of therapy-related myeloid neoplasms34
Lipid metabolic reprogramming and associated ferroptosis in osteosarcoma: From molecular mechanisms to potential targets27
Macrophage heterogeneity in bone metastasis25
State-of-the-art of minimally invasive treatments of bone metastases21
Radiomics model based on MRI to differentiate spinal multiple myeloma from metastases: A two-center study20
#1. Acid ceramidase (ASAH1) is a key mediator of drug resistance in relapsed/refractory multiple myeloma20
Adoption of adjuvant bisphosphonates for early breast cancer into standard clinical practice: Challenges and lessons learnt from comparison of the UK and Australian experience20
#41. Discovery of novel tubulin code in bone metastasis of breast cancer20
Frequency and reason for reoperation following non-invasive expandable endoprostheses: A systematic review20
Comprehensive landscape of TGFβ-related signature in osteosarcoma for predicting prognosis, immune characteristics, and therapeutic response18
Targeting the IGF/PI3K/mTOR pathway and AXL/YAP1/TAZ pathways in primary bone cancer18
A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva®) in patients with bone metastasis from solid tumors18
0.22393298149109